Amgen Inc. Repayments of Commercial Paper
Amgen Inc. (AMGN) reported Repayments of Commercial Paper of $12.30 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfCommercialPaper · last filed 2020-02-12
- Amgen Inc. repayments of commercial paper for fiscal 2017 was $12.30B.
- Amgen Inc. repayments of commercial paper for fiscal 2013 was $0.00.
- Amgen Inc. repayments of commercial paper for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- Amgen Inc. repayments of commercial paper for fiscal 2011 was $762.00M.
| Period end | Repayments of Commercial Paper 12 month |
|---|---|
| 2017-12-31 | $12.30B 10-K · filed 2020-02-12 |
| 2013-12-31 | $0.00 10-K · filed 2014-02-24 |
| 2012-12-31 | $0.00 10-K · filed 2014-02-24 |
| 2011-12-31 | $762.00M 10-K · filed 2014-02-24 |
| 2010-12-31 | $0.00 10-K · filed 2013-02-27 |
| 2009-12-31 | $0.00 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |